Top 5 Biotechnology Angel Investors in New Zealand in May 2026
Top 5 Biotechnology Angel Investors in New Zealand in May 2026
| Investor | Biotechnology New Zealand investments |
|---|---|
| Paul Davidson | 1 |
| Serge van Dam | 1 |
| Melanie Melanie | 1 |
| David Ross | 1 |
| Marko Bogoievski | 1 |
Reach every investor
Get a list of investors who already back your industry, stage, and country. Emails & phones included.
Find investors — It's Free!
Paul Davidson joined private equity group, West Coast Capital in 2005 following a successful career in corporate law in the UK, the US and Commonwealth of Independent States. As an active partner in West Coast Capital as well as providing legal counsel, Paul focusses on deal sourcing and transacting.Since joining the group, Paul has successfulyled the acquisition and delisting from the LSE of the UK's largest garden centre business, Wyevale as well as a series of acquisitions and disposals.Prior to joining West Coast Capital headed the corporate team of UK lawyers, McGrigors.In late 1994 Paul was seconded to an oil and gas company called JKX whose focus was on the former Soviet Union, primarily in Ukraine, Georgia and the Russian Federation. JKX listed on the London Stock Exchange in mid 1995 and at that time Paul joined the company as its Legal Director on a full time basis. During his time as Legal Director, Paul gained wide commercial experience as the company concluded a number of transactions throughout the former Soviet Union.
Show more...Investment focus
- SaaS, FinTech, Privacy
- Seed, Series A, Series B
- Finland, New Zealand, United Kingdom
Portfolio highlights
- Daisy Lab — Daisy Lab pioneers precision fermentation technology in New Zealand
- TVSquared — With trusted, independent attribution and partnerships with DSPs, publishers, advertisers and MVPDs, TVSquared measures the effectiveness of TV advertising through an infinitely scalable platform for linear, addressable and OTT/CTV.
- Ubisecure — Ubisecure B2B IAM, Legal Entity Identifiers LEI, IDaaS and hybrid identity management. European SSO, MFA, LEI made easy.
Serge has a depth of experience in technology startups that is difficult to rival. As CMO of M-Com, Serge led the growth of M-Com from a four person mobile commerce development company to the world's most successful provider of mobile banking and payment solutions (in both licensed and SaaS categories). He has since held executive levelpositions and Directorships, including as Chair on four boards, of many successful B2B SaaS companies. He is also an avid investor.
Show more...Investment focus
- Biotechnology, Product Research
- Seed
- New Zealand
Portfolio highlights
- Daisy Lab — Daisy Lab pioneers precision fermentation technology in New Zealand
Investor
Show more...Investment focus
- Biotechnology, Product Research
- Seed
- New Zealand
Portfolio highlights
- Daisy Lab — Daisy Lab pioneers precision fermentation technology in New Zealand
David Ross
Show more...Investment focus
- Biopharma, Biotechnology
- Seed
- New Zealand
Portfolio highlights
- Helico — Helico is developing a proprietary computational platform for synthetic biology research using modelling tools and AI-based prediction algorithms. The long-term aim is to develop a seed bank of different drugs able to be licensed to grow medical supplies in confined greenhouses anywhere in the world.
Marko retired as CEO of Morrison & Co in 2021 after 13 years of leading the business. He continues to provide guidance for investments in telecommunications and digital infrastructure. His 30 year career has been in the infrastructure and technology sectors in a variety of senior finance, operational and sales roles in the United States and NewZealand. Prior to joining Morrison & Co in 2008, Marko was CFO of Telecom NZ, responsible for corporate finance, M&A and group strategy. Marko is Chair of Vodafone New Zealand.
Show more...Investment focus
- Biotechnology, Manufacturing
- Funding Round
- New Zealand
Portfolio highlights
- Pictor — PictorDx offers a flexible multiplex proteomics platform that delivers multiple biomarker insights simultaneously and cost-effectively for multiple sample types
Contact investors today
Find who invests in your industry, stage, and country in 5 minutes.
Find investors — It's Free!
